Medications for substance use disorders

Social Work in Public Health

Volumn 28, Issue 3-4, 2013, Pages 264-278

  Douaihy, Antoine B ^a   Kelly, Thomas M ^b   Sullivan, Carl ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

alcohol; detoxification; nicotine; opioids; relapse prevention; social workers; Substance use disorders

Indexed keywords

BUPRENORPHINE; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ALCOHOL; DISEASE TREATMENT; DRUG USER; TOBACCO; TOXICITY;

ADDICTION; ALCOHOLISM; BEHAVIOR THERAPY; HUMAN; RECURRENT DISEASE; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; ALCOHOLISM; ANALGESICS, OPIOID; BEHAVIOR THERAPY; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; DISULFIRAM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; RECURRENCE; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER;

NICOTIANA TABACUM;

EID: 84879106171     PISSN: 19371918     EISSN: 1937190X     Source Type: Journal    
DOI: 10.1080/19371918.2013.759031     Document Type: Review

References (83)

1. Anton, R. F. (2001). Pharmacologic approaches to the management of alcoholism. Journal of Clinical Psychiatry, 62(Suppl 20), 11-17.
2. Anton, R. F., O'Malley, S. S., Ciraulo, D. A., Couper, D., Donovan, D. M., Gastfriend, D. R., COMBINE Study Research Group. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: A randomized controlled trial. Journal of the American Medical Association, 295, 2003-2017.
3. Banys, P. (1988). The clinical use of disulfiram (Antabuse): A review. Journal of Psychoactive Drugs, 20(3), 243-261.
4. Barber, W. S., & O'Brien, C. P. (1999). Pharmacotherapies. In B. S. McCrady & E. E. Epstein (Eds.), Addictions: A comprehensive guidebook (pp. 347-369). New York, NY: Oxford University Press.
5. Batki, S. L., Kauffman, J. F., Marion, I., Parrino, M. W., & Woody, G. E. (2005). Medication assisted treatment for opioid addiction in opioid treatment programs (Vol. 43, TIP series). Rockville, MD: Center for Substance Abuse Treatment.
6. Batra, A. (2011). Treatment of tobacco dependence. Deutsches Arzteblatt International, 108(33), 555-564.
7. Bobo, J. K., McIlvain, H. E., Lando, H. A., Walker, R. D., & Leed-Kelly, A. (1998). Effect of smoking cessation counseling on recovery from alcoholism: Findings from a randomized community intervention trial. Addiction, 93(6), 877-887.
8. Buonopane, A., & Petrakis, I. L. (2005). Pharmacotherapy of alcohol use disorders. Substance Use & Misuse, 40(13/14), 2001-2020, 2043-2048.
9. Carmody, T. P., Delucchi, K., Duncan, C. L., Banys, P., Simon, J. A., Solkowitz, S. N., Hall, S. M. (2012). Intensive intervention for alcohol-dependent smokers in early recovery: A randomized trial. Drug and Alcohol Dependence, 122(3), 186-194.
10. Carroll, K. M., & Schottenfeld, R. (1997). Nonpharmacologic approaches to substance abuse treatment. Medical Clinics of North America, 81(4), 927-944.
11. Carroll, K. M., Fenton, L. R., Ball, S. A., Nich, C., Frankforter, T. L., Shi, J., & Rounsaville, B. J. (2004). Efficacy of disulfiram and cognitive behavioral therapy I cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry, 61(3), 264-272.
12. Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., O'Neill, B. T. (2005). Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry, 48(1), 3474-3477.
13. Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005). A double-blind, placebocontrolled trial of Modafinil for cocaine dependence. Neuropsychopharmacology, 30, 205-211.
14. Dattilio, F. M. (2009). Comprehensive cognitive-behavior therapy with couples and families. New York, NY: Guilford.
15. Donny, E. C., Walsh, S. L., Bigelow, G. E., Eissenberg, T., & Stitzer, M. L. (2002). High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology, 161(2), 202-212.
16. Ebbert, J. O., Hays, J. T., & Hurt, R. D. (2010). Combination pharmacotherapy for stopping smoking: What advantages does it offer? Drugs, 70(6), 643-650.
17. Farre, M., Mas, A., Torrens, M., Moreno, V., & Cami, J. (2002). Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug and Alcohol Dependence, 65(3), 283-290.
18. Fischer, G., Ortner, R., Rohrmeister, K., Jagsch, R., Baewert, A., Langer, M., & Aschauer, H. (2006). Methadone versus buprenorphine in pregnant addicts: A double-blind, double-dummy comparison study. Addiction, 101, 275-281.
19. Fuller, R. K., Branchey, L., Brightwell, D. R., Derman, R. M., Emrick, C. D., Iber, F. L., Shaw, S. (1986). Disulfiram treatment of alcoholism: A Veterans Administration cooperative study. Journal of the American Medical Association, 256(11), 1449-1455.
20. Fuller, R. K., & Gordis, E. (2004). Does disulfiram have a role in alcoholism treatment today? Addiction, 99(1), 21-24.
21. Garbutt, J. C. (2009). The state of pharmacotherapy for the treatment of alcohol dependence. Journal of Substance Abuse Treatment, 36(1), S15-23; quiz S24-25.
22. Garbutt, J. C., Kranzler, H. R., O'Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Vivitrex Study Group. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. Journal of the American Medical Association, 293(13), 1617-1625.
23. Gastfriend, D. R. (2011). Intramuscular extended-release naltrexone: Current evidence. Annals of the New York Academy of Sciences, 1216, 144-166.
24. George, T. P., & O'Malley, S. S. (2004). Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences, 25(1), 42-48.
25. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., Varenicline Phase 3 Study Group (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 296(1), 47-55.
26. Gonzalez, G., Oliveto, A., & Kosten, T. R. (2004). Combating opiate dependence: A comparison among the available pharmacological options. Expert Opinion on Pharmacotherapy, 5(4), 713-725.
27. Gonzalez, J. P., & Brogden, R. N. (1988). Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 35(3), 192-213.
28. Gourlay, S. G., Stead, L. F., & Benowitz, N. L. (2004). Clonidine for smoking cessation. Cochrane Database of Systematic Reviews, (3), CD000058.
29. Hatsukami, D. K., Rennard, S., Jorenby, D., Fiore, M., Koopmeiners, J., de Vos, A., Pentel, P. R. (2005). Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology & Therapeutics, 78, 456-467.
30. Hays, J. T. (2011). Varenicline for smoking cessation: Is it a heartbreaker?CanadianMedical Association Journal, 183(12), 1346-1347.
31. Hays, J. T., & Ebbert, J. O. (2010). Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs, 70(18), 2357-2372.
32. Heffner, J. L., Tran, G. Q., Johnson, C. S., Barrett, S. W., Blom, T. J., Thompson, R. D. & Anthenelli, R. M. (2010). Combining motivational interviewing with compliance enhancement therapy (MI-CET): Development and preliminary evaluation of a new manual-guided psychosocial adjunct to alcohol dependence pharmacotherapy. Journal of Studies on Alcohol and Drugs, 71, 61-70.
33. Henningfield, J. E., Fant, R. V., Buchhalter, A. R., & Stitzer, M. L. (2005). Pharmacotherapy for nicotine dependence. CA: A Cancer Journal for Clinicians, 55(5), 281-299.
34. Holt, L. J., Litt, M. D., & Cooney, N. L. (2012). Prospective analysis of early lapse to drinking and smoking among individuals in concurrent alcohol and tobacco treatment. Psychology of Addictive Behaviors, 26(3), 561-572.
35. Hopkins, J. S., Garbutt, J. C., Poole, C. L., West, S. L., & Carey, T. S. (2002). Naltrexone and acamprosate:Meta analysis of two medical treatments for alcoholism. Alcoholism: Clinical and Experimental Research, 26(Suppl), 130A.
36. Hughes, J. C., & Cook, C. C. (1997). The efficacy of disulfiram: A review of outcome studies. Addiction, 92(4), 381-395.
37. Hughes, J. R., Stead, L. F., & Lancaster T. (2004). Antidepressants for smoking cessation. The Cochrane Library. doi:10. 1002/14651858.CD000031
38. Hughes, J. R., Stead, L. F., & Lancaster, T. (2005). Nortriptyline for smoking cessation: A review. Nicotine and Tobacco Research, 7(4), 491-499.
39. Hurt, R. D., Sachs, D. P., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Sullivan, P.M. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine, 337(17), 1195-1202.
40. Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Ma, J. Z. (2003). Oral topiramate for treatment of alcohol dependence: A randomized controlled trial. Lancet, 361(9370), 1677-1685.
41. Johnson, B. A., Rosenthal, N., Capece, J. A., Wiegand, F., Mao, L., Beyers, K., Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group (2007). Topiramate for treating alcohol dependence: A randomized controlled trial. Journal of the American Medical Association, 298(14), 1641-1651.
42. Jorenby, D. (2002). Clinical efficacy of bupropion in the management of smoking cessation. Drugs, 62(Suppl 2), 25-35.
43. Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012). Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors, 37(1), 11-24.
44. Kosten, T., & Owens, S. M. (2005). Immunotherapy for the treatment of drug abuse. Pharmacology & Therapeutics, 108(1), 76-85.
45. Kosten, T. R., & O'Connor, P. G. (2003).Management of drug and alcohol withdrawal. New England Journal of Medicine, 348(18), 1786-1795.
46. Kreek, M. J., Oratz, M., & Rothschild, M. A. (1978). Hepatic extraction of long- and short-acting narcotics in the isolated perfused rabbit liver. Gastroenterology, 75(1), 88-94.
47. Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., Rosenheck, R. A., & Veterans Affairs Naltrexone Cooperative Study 425 Group. (2001). Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine, 345(24), 1734-1739.
48. Lancaster, T., & Stead, L. F. (2000). Individual behavioural counseling for smoking cessation. Cochrane Database of Systematic Reviews, (2), CD001292.
49. Lancaster, T., Stead, L., Silagy, C., & Sowden, A. (2000). Effectiveness of interventions to help people stop smoking: Findings from the Cochrane Library. British Medical Journal, 321(7257), 355-358.
50. Lee, J. D., Grossman, E., DiRocco, D., Truncali, A., Hanley, K., Stevens, D., Gourevitch, M. N. (2010). Extendedrelease naltrexone for treatment of alcohol dependence in primary care. Journal of Substance Abuse Treatment, 39(1), 14-21.
51. LeStrat, Y., Ramoz, N., & Gorwood, P. (2010). In alcohol-dependent drinkers, what does the presence of nicotine dependence tell us about psychiatric and addictive disorders comorbidity? Alcohol and Alcoholism, 45(2), 167-172.
52. Littleton, J. M. (2007). Acamprosate in alcohol dependence: Implications of a unique mechanism of action. Journal of Addiction Medicine, 1(3), 115-125.
53. Lobmaier, P., Kornor, H., Kunoe, N., & Bjorndal, A. (2008). Sustained-release naltrexone for opioid dependence.Cochrane Database of Systematic Reviews, (2), CD006140.
54. Mason, B. J. (2003). Acamprosate and naltrexone treatment for alcohol dependence: An evidence-based risk-benefits assessment. European Neuropsychopharmacology, 13(6), 469-475.
55. Mason, B. J., Goodman, A. M., Chabac, S., & Lehert, P. (2006). Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. Journal of Psychiatric Research, 40(5), 383-393.
56. Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2003). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, (2), CD002209.
57. Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2), CD002207.
58. McCaul, M. E., & Petry, N. M. (2003). The role of psychosocial treatments in pharmacotherapy for alcoholism. American Journal of Addiction, 12(Suppl 1), S41-S52.
59. McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E., & O'Brien, C. P. (1993). The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association, 269(15), 1953-1959.
60. McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kieber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association, 284(13), 1689-1695.
61. Meyers, R. J., Smith, J. E., & Lash, D. N. (2003). The community reinforcement approach. Recent Developments in Alcoholism, 16, 183-195.
62. Miller, W. R., Yahne, C. E., Moyers, T. B., Martinez, J., & Pirritano, M. (2004). A randomized trial of methods to help clinicians learn motivational interviewing. Journal of Consulting and Clinical Psychology, 72(6), 1050-1062.
63. Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2006). Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews, (1), CD001333.
64. Nides, M. (2008). Update on pharmacologic options for smoking cessation treatment. American Journal of Medicine, 121(4 Suppl 1), S20-S31.
65. O'Brien, C. P. (2005). Anticraving medications for relapse prevention: A possible new class of psychoactive medications. American Journal of Psychiatry, 162(8), 1423-1431.
66. Petry, N. M. (2011). Contingency management:What it is and why psychiatrists should want to use it. Psychiatrist, 35(5), 161-163.
67. Pettinati, H. M. (2004). Antidepressant treatment of co-occurring depression and alcohol dependence. Biological Psychiatry, 56(10), 785-792.
68. Pettinati, H. M., Volpicelli, J. R., Pierce, J. D., & O'Brien, C. P. (2000). Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases, 19(1), 71-83.
69. Roth, A., Hogan, I., & Farren, C. (1997). Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. Journal of Substance Abuse Treatment, 14(1), 19-22.
70. Rychtarik, R. G., Connors, G. J., Dermen, K. H., & Stasiewicz, P. R. (2000). Alcoholics Anonymous and the use of medications to prevent relapse: An anonymous survey of member attitudes. Journal of Studies on Alcoholism, 61(1), 134-138.
71. Shorter, D., & Kosten, T. R. (2011). Novel pharmacotherapeutic treatments for cocaine addiction. BMC Medicine, 9, 119-127.
72. Sweeney, C. T., Fant, R. V., Fagerstrom, K. O., McGovern, J. F., & Henningfield, J. E. (2001). Combination nicotine replacement therapy for smoking cessation: Rationale, efficacy and tolerability. CNS Drugs, 15(6), 453-467.
73. Swift, R. M. (2003). Topiramate for the treatment of alcohol dependence: Initiating abstinence. Lancet, 361(9370), 1666-1667.
74. Tambour, S., & Quertermont, E. (2007). Preclinical and clinical pharmacology of alcohol dependence. Fundamental & Clinical Pharmacology, 21(1), 9-28.
75. Tonigan, J. S. (2003). Changing AA practices and outcomes: Project MATCH three-year follow-up. Alcoholism: Clinical and Experimental Research, 27(3), 526-528.
76. Tonigan, J. S., & Kelly, J. F. (2004). Beliefs about AA and the use of medications: A comparison of three groups of AA-exposed alcohol dependent persons. Alcoholism Treatment Quarterly, 22(2), 67-78.
77. Tonnesen, P. (2009). Smoking cessation: How compelling is the evidence? A review. Health Policy, 91(Suppl 1), S15-S25.
78. van Meijgaard, J., & Fielding, J. E. (2012). Estimating benefits of past, current and future reductions in smoking rates using a comprehensive model with competing causes of death. Preventing Chronic Disease, 9, 110295.
79. Volpicelli, J. R. (2001). Alcohol abuse and alcoholism: An overview. Journal of Clinical Psychiatry, 62(Suppl 20), 4-10.
80. Weinstein, A. M., & Gorelick, D. A. (2011). Pharmacological treatment of cannabis dependence. Current Pharmaceutical Design, 17(14), 1351-1358.
81. West, R., Hajek, P., Foulds, J., Nilsson, F., May, S., & Meadows, A. (2000). A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology, 149(3), 198-202.
82. Wu, P., Wilson, K., Dimoulas, P., & Mills, E. J. (2006). Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health, 6, 300-315.
83. Zweben, A., & Zuckoff, A. (2002). Motivational interviewing and treatment adherence. In W. R. Miller & S. Rollnick (Eds.), Motivational interviewing: Preparing people for change (2nd ed., pp. 299-319). New York, NY: Guilford Press.